--- title: "Nkarta (NKTX) news: offering" url: "https://aibio.space/companies/nkarta/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NKTX offering news: Nkarta sets up $100,000,000 at-the-market stock program with Stifel. Nkarta, Inc. (NASDAQ: NKTX), United States." --- NKTX Nkarta, Inc. NASDAQ · United States # Nkarta (NKTX) news NKTX offering news Financings · 2026-03-25 ## [Nkarta sets up $100,000,000 at-the-market stock program with Stifel](https://aibio.space/news/nkarta-sets-up-100-000-000-market-stock-program-stifel/) Nkarta set up a $100 million at-the-market program with Stifel on March 25, 2026, with commissions of up to 3%. Its 2025 net loss was $104.1 million, and its operating cash use was $88.7 million. ## Latest Nkarta news 1. 2025-03-26 Distress [Nkarta to cut 34% of workforce in restructuring, expects cash runway into 2029](https://aibio.space/news/nkarta-cut-34-percent-workforce-restructuring-expects-cash-runway-2029/) Nkarta is cutting 53 positions, about 34% of its staff, at an expected cost of $5.5 million to $6.5 million. It says its $380.5 million of cash and investments can fund operations into 2029, while the first clinical data from its lead program are not due until the second half of 2025. 2. 2025-03-26 Distress [Nkarta cuts 34% of workforce (53 positions), sees $380.5 million in cash lasting into 2029](https://aibio.space/news/nkarta-cuts-34-percent-workforce-53-positions-sees-380-5-million-cash/) Nkarta is cutting 34% of its workforce and freezing some hires, and it says $380.5 million in cash will fund operations into 2029. Its release reports no efficacy data for NKX019, and the trials enroll small groups. ## Nkarta at a glance - **Ticker**: NKTX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $182.8 million ### Related companies - [Curis](https://aibio.space/companies/curis/) NASDAQ: CRIS - [MBX Biosciences](https://aibio.space/companies/mbx-biosciences/) NASDAQ: MBX - [EHOUSE GLOBAL INC](https://aibio.space/companies/ehouse-global/) OTC: EHOS - [Monte Rosa Therapeutics](https://aibio.space/companies/monte-rosa-therapeutics/) NASDAQ: GLUE - [Alector](https://aibio.space/companies/alector/) NASDAQ: ALEC - [Amgen](https://aibio.space/companies/amgen/) NASDAQ: AMGN - [Vincerx Pharma](https://aibio.space/companies/vincerx-pharma/) OTC: VINC - [Taysha Gene Therapies](https://aibio.space/companies/taysha-gene-therapies/) NASDAQ: TSHA ### Also on NASDAQ - [Cronos Group](https://aibio.space/companies/cronos/) CRON - [Research Alliance Corp III](https://aibio.space/companies/research-alliance-iii/) RACC - [ANI Pharmaceuticals](https://aibio.space/companies/ani-pharmaceuticals/) ANIP - [PULSE BIOSCIENCES, INC.](https://aibio.space/companies/pulse-biosciences/) PLSE - [Sionna Therapeutics](https://aibio.space/companies/sionna-therapeutics/) SION - [Medicus Pharma](https://aibio.space/companies/medicus-pharma/) MDCX ## Nkarta annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$0](https://www.sec.gov/Archives/edgar/data/1787400/000178740026000006/) | [$0](https://www.sec.gov/Archives/edgar/data/1787400/000095017025045262/) | | Research and development | [$90.4 million](https://www.sec.gov/Archives/edgar/data/1787400/000178740026000006/) | [$96.7 million](https://www.sec.gov/Archives/edgar/data/1787400/000178740026000006/) | | Net income (loss) | [-$104.1 million](https://www.sec.gov/Archives/edgar/data/1787400/000178740026000006/) | [-$108.8 million](https://www.sec.gov/Archives/edgar/data/1787400/000178740026000006/) | | Cash from operations | [-$88.7 million](https://www.sec.gov/Archives/edgar/data/1787400/000178740026000006/) | [-$99.7 million](https://www.sec.gov/Archives/edgar/data/1787400/000178740026000006/) | | Cash and equivalents | [$39.6 million](https://www.sec.gov/Archives/edgar/data/1787400/000178740026000017/) | [$27.9 million](https://www.sec.gov/Archives/edgar/data/1787400/000178740026000006/) | | Short-term investments | [$236.6 million](https://www.sec.gov/Archives/edgar/data/1787400/000178740026000017/) | [$239.5 million](https://www.sec.gov/Archives/edgar/data/1787400/000178740026000006/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $25.0 million, plus short-term investments of $157.8 million, $182.8 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Nkarta Has Nkarta raised money recently? Our latest story on this, dated Mar 25, 2026: "Nkarta sets up $100,000,000 at-the-market stock program with Stifel". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nkarta-sets-up-100-000-000-market-stock-program-stifel/). What is the ticker symbol of Nkarta? Nkarta, Inc. trades under the ticker NKTX on NASDAQ. Where is Nkarta listed? Nkarta, Inc. is listed on NASDAQ. What is the SEC CIK of Nkarta? The SEC Central Index Key (CIK) for Nkarta, Inc. is 1787400. Its filings are on SEC EDGAR. How many shares does Nkarta have outstanding? 71,624,791 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-10. Which country or territory is Nkarta listed under? Our directory records Nkarta, Inc. under United States. What does Nkarta do? Our directory classifies Nkarta, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Nkarta? The ISIN recorded for Nkarta, Inc. is US65487U1088. Does aibio.space cover Nkarta? aibio.space lists Nkarta, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Nkarta incorporated? SEC records list its state or country of incorporation as DE. What was Nkarta's revenue last year? $0 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Nkarta profitable? Nkarta, Inc. reported a net loss of $104.1 million for the fiscal year ended Dec 31, 2025, and used $88.7 million of cash in operations, per its annual report to the SEC. How much does Nkarta spend on research and development? $90.4 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Nkarta have? $182.8 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Nkarta (NKTX) stock news? Our latest story on Nkarta, dated Mar 25, 2026: "Nkarta sets up $100,000,000 at-the-market stock program with Stifel". Nkarta set up a $100 million at-the-market program with Stifel on March 25, 2026, with commissions of up to 3%. Its 2025 net loss was $104.1 million, and its operating cash use was $88.7 million. [Source](https://aibio.space/news/nkarta-sets-up-100-000-000-market-stock-program-stifel/). ## Investor discussion: Nkarta Members talk about Nkarta (NKTX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Nkarta, newest first. Each line links the filing it comes from. 1. 2026-03-25 Financings Reported a financing. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1787400/000114036126011152/ny20068088x1_s3.htm) 2. 2025-03-26 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1787400/000095017025045231/nktx-ex99_1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NKTX on TradingView](https://www.tradingview.com/symbols/NASDAQ-NKTX/). ## SEC filings and registration - **SEC name**: Nkarta, Inc. - **CIK**: 1787400 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: NKTX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080 - **Phone**: (925) 407-1049 - **Shares outstanding**: 71,624,791 as of 2026-08-05 (10-Q filed 2026-08-10) ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1787400/000178740026000017/nktx-20260630.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1787400/000119312526342402/nktx-20260810.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1787400/000119312526267830/nktx-20260610.htm) filed 2026-06-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/1787400/000178740026000013/nktx-20260331.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1787400/000178740026000012/nktx-20260512.htm) filed 2026-05-12 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1787400/000114036126016403/ny20064125x1_def14a.htm) filed 2026-04-23 - [424B5](https://www.sec.gov/Archives/edgar/data/1787400/000114036126013179/ny20068088x2_424b5.htm) filed 2026-04-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1787400/000178740026000008/nktx-20260325.htm) filed 2026-03-26 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001787400), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Nkarta, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NKTX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Nkarta, Inc. - **Ticker**: NKTX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US65487U1088 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-NKTX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/nkarta/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Nkarta (NKTX) news: offering", 2026-10-31, https://aibio.space/companies/nkarta/